Mahkam Zanganeh - 13 Nov 2023 Form 4 Insider Report for Pulse Biosciences, Inc. (PLSE)

Role
Director
Signature
/s/ Kenneth B. Stratton, as Attorney-in-Fact
Issuer symbol
PLSE
Transactions as of
13 Nov 2023
Net transactions value
+$162,800
Form type
4
Filing time
15 Nov 2023, 17:37:07 UTC
Previous filing
16 Oct 2023
Next filing
13 Dec 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PLSE Common Stock Options Exercise $42,800 +20,000 +3.8% $2.14 548,836 13 Nov 2023 Direct
transaction PLSE Common Stock Options Exercise $120,000 +56,075 +10% $2.14 604,911 13 Nov 2023 Direct
holding PLSE Common Stock 27,000 13 Nov 2023 Immediate family member 1
holding PLSE Common Stock 14,000 13 Nov 2023 Immediate family member 2
holding PLSE Common Stock 107,074 13 Nov 2023 Immediate family member 3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PLSE Stock Option (right to buy) Options Exercise $0 -20,000 -100% $0.000000* 0 13 Nov 2023 Common Stock 20,000 $2.14 Direct F1
transaction PLSE Stock Option (right to buy) Options Exercise $0 -56,075 -100% $0.000000* 0 13 Nov 2023 Common Stock 56,075 $2.14 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Pursuant to the Company's Amended and Restated Outside Director Compensation Policy, this option vested on a monthly basis following the Company's 2022 Annual Stockholder Meeting.
F2 Pursuant to the Company's Amended and Restated Outside Director Compensation Policy, this option vested on a quartetrly basis following the Company's 2022 Annual Stockholder Meeting.